10x Genomics (NASDAQ:TXG) Trading Up 9.4% – Should You Buy?

10x Genomics (NASDAQ:TXG)’s stock price rose 9.4% during mid-day trading on Thursday . The company traded as high as $16.97 and last traded at $17.12. Approximately 413,128 shares traded hands during mid-day trading, a decline of 87% from the average daily volume of 3,210,332 shares. The stock had previously closed at $15.65.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. upped their target price on 10x Genomics from $13.00 to $15.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Zacks Research cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Morgan Stanley dropped their target price on shares of 10x Genomics from $18.00 to $17.00 and set an “overweight” rating for the company in a report on Tuesday, August 12th. Wall Street Zen downgraded 10x Genomics from a “buy” rating to a “hold” rating in a research report on Saturday, November 15th. Finally, Piper Sandler lifted their price objective on shares of 10x Genomics from $15.00 to $19.00 and gave the company a “neutral” rating in a research note on Tuesday, November 11th. Six research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, 10x Genomics has an average rating of “Hold” and a consensus price target of $14.88.

10x Genomics Price Performance

The firm has a market cap of $2.32 billion, a PE ratio of -29.58 and a beta of 2.13. The business’s fifty day moving average is $13.41 and its 200-day moving average is $12.30.

10x Genomics (NASDAQ:TXG) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.05. The company had revenue of $149.00 million during the quarter, compared to analyst estimates of $142.50 million. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. 10x Genomics’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter last year, the business posted ($0.30) EPS. 10x Genomics has set its Q4 2025 guidance at EPS. Analysts forecast that 10x Genomics will post -1.43 EPS for the current year.

Institutional Investors Weigh In On 10x Genomics

Institutional investors have recently added to or reduced their stakes in the business. CIBC Bancorp USA Inc. purchased a new position in shares of 10x Genomics in the third quarter worth about $134,000. Jacobs Levy Equity Management Inc. boosted its holdings in 10x Genomics by 22.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,947,989 shares of the company’s stock worth $34,462,000 after buying an additional 550,250 shares during the period. CANADA LIFE ASSURANCE Co grew its stake in 10x Genomics by 14.9% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 25,365 shares of the company’s stock valued at $287,000 after buying an additional 3,296 shares in the last quarter. XTX Topco Ltd raised its holdings in 10x Genomics by 41.0% during the 3rd quarter. XTX Topco Ltd now owns 81,070 shares of the company’s stock valued at $948,000 after acquiring an additional 23,555 shares during the period. Finally, Voleon Capital Management LP raised its holdings in 10x Genomics by 73.9% during the 3rd quarter. Voleon Capital Management LP now owns 306,101 shares of the company’s stock valued at $3,578,000 after acquiring an additional 130,094 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.